Browse the evidence

Semaglutide treatment in Type 2 Diabetes Mellitus patients significantly reduces HbA1c, fasting plasma glucose, and body weight while improving renal markers (ACR) over a 12-month period.

If you have Type 2 Diabetes, Semaglutide is a highly effective treatment for lowering blood sugar (HbA1c) and losing weight. It is taken as a once-weekly injection, starting at a low dose to minimize side effects like nausea. This treatment also helps protect kidney function by reducing albumin in the urine. Consistency is key, as benefits are maintained over time.

Tirzepatide (2.5 mg weekly) significantly improves glycemic control and reduces body weight in patients with type 2 diabetes during Ramadan fasting, with a favorable safety profile characterized by mild gastrointestinal side effects and no reported hypoglycemia.

If you have type 2 diabetes and plan to fast during Ramadan, tirzepatide (2.5 mg weekly) can help improve your blood sugar and weight without causing low blood sugar. You might experience mild stomach issues like nausea, but these are usually manageable and do not require stopping the medication or breaking your fast. Consult your doctor to ensure it fits your overall treatment plan.

In patients with diabetes, the combination of a healthy diet style and sleep disorders significantly moderates the relationship with waist circumference, indicating that sleep disturbances can negate or alter the protective effects of healthy dietary patterns on abdominal obesity.

For diabetic patients, managing waist circumference requires attention to both diet and sleep. Even with a healthy diet, sleep disorders can negatively impact abdominal obesity. Prioritize sleep hygiene alongside dietary changes to maximize metabolic benefits.

Consumption of sugar-sweetened beverages (SSBs) is positively associated with increased waist circumference and BMI in diabetic patients, independent of other dietary factors.

Reduce or eliminate sugar-sweetened beverages to help manage waist circumference and BMI. This is a key dietary modification for diabetic patients.

Higher relative intake of dietary protein is inversely associated with the risk of coronary artery disease (CAD), based on observational data.

If you are concerned about coronary artery disease, this study suggests that ensuring adequate protein intake may be beneficial. Higher relative protein intake was linked to a lower risk of CAD. Include protein-rich foods in your diet. Consult your doctor for personalized advice, especially if you have existing kidney conditions.

Discontinuation or interruption of GLP-1 agonist therapy (semaglutide) leads to rapid weight regain and loss of cardiometabolic benefits, with patients regaining approximately two-thirds of lost weight within one year.

If you stop taking semaglutide, you will likely regain about two-thirds of the weight you lost and lose the heart and blood sugar benefits within a year. The drug works only as long as you take it. If you face a supply shortage or side effects, do not just stop; contact your provider immediately to switch to an alternative or manage the transition, as stopping leads to rapid regain.

Mediterranean and low-carbohydrate diets combined with exercise reduce cardiovascular and metabolic risk factors in prostate cancer patients undergoing androgen deprivation therapy (ADT).

If you are undergoing hormone therapy for prostate cancer, adopting a Mediterranean or low-carbohydrate diet alongside regular exercise can help manage metabolic risks like weight gain and blood sugar issues. While the benefits are clear, sticking to these changes long-term can be challenging, so focus on consistency over perfection.

Multidisciplinary care and community involvement improve accountability and outcome durability for prostate cancer patients undergoing ADT.

To maintain the benefits of diet and exercise during ADT, consider engaging with multidisciplinary care teams or community support groups. These resources can help you stay accountable and sustain your progress over time.

GLP-1 and GLP-1/GIP receptor agonists are associated with lower exposure-adjusted mortality rates compared to non-GLP-1 weight management agents.

Beyond weight loss, GLP-1 and GLP-1/GIP agonists may offer a mortality benefit compared to older weight loss drugs. This is a significant advantage for patients with obesity-related comorbidities.

Herbal medicine interventions for obesity exhibit pleiotropic mechanisms, including thermogenesis, inhibition of pancreatic lipase, reduced food intake, and increased lipolysis, mediated by secondary metabolites like flavonoids and saponins.

Herbal medicines for obesity work through multiple pathways, such as boosting metabolism (thermogenesis), blocking fat absorption (lipase inhibition), and reducing appetite. They are not single-target drugs but complex mixtures that may offer a safer profile than prescription weight-loss drugs, though they still require careful monitoring.

Targeting thermogenesis via β3-adrenergic receptor (β3-AR) activation can increase energy expenditure and promote brown adipose tissue (BAT) activity, offering a complementary mechanism to GLP-1 agonists for obesity management.

Research is actively exploring medications that activate brown fat (thermogenesis) to burn more calories. While not yet standard care, these drugs (like β3-agonists) work by increasing energy expenditure. They may eventually be used alongside GLP-1 medications to overcome weight loss plateaus. Current options are limited by side effects, but newer, more selective drugs are showing promise in clinical trials.

GLP-1 receptor agonists, particularly semaglutide and tirzepatide, are associated with an increased risk of non-scarring hair loss (telogen effluvium and androgenetic alopecia), primarily driven by rapid weight loss and nutritional deficits rather than direct drug toxicity.

If you are using semaglutide or tirzepatide and notice hair shedding, it is likely due to rapid weight loss or nutritional deficits rather than permanent drug damage. Ensure adequate protein and micronutrient intake (iron, zinc) and consider slowing dose escalation. The risk is highest with these specific drugs and in females, but often stabilizes as weight loss plateaus.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce alcohol consumption, cravings, and alcohol-related hospitalizations in patients with Alcohol Use Disorder (AUD), particularly in obese subgroups.

If you have AUD, especially if you are obese or have Type 2 Diabetes, GLP-1 medications (like Semaglutide or Exenatide) are showing promise in reducing drinking and cravings. They work by changing how your brain rewards alcohol. While they are injections and can cause stomach issues, these side effects often fade. They are not yet the standard first-line treatment for all AUD, but they are a strong option to discuss with your doctor, particularly if other treatments haven't worked.

In older women, substituting total or animal protein with fat or carbohydrates is negatively associated with appendicular skeletal muscle mass (ASMM) in cross-sectional analyses, but this association disappears in longitudinal analyses over 20 years.

For older women, simply eating more protein than fat or carbs might not protect muscle mass in the long run (20 years). While cross-sectional data shows a link between lower protein and lower muscle mass, long-term tracking shows no clear benefit. Focus on overall diet quality and physical activity rather than just maximizing protein intake.

Short-term resistance training (4 weeks) combined with medium-dose cheese supplementation (13.4g protein/week) optimizes body composition and lipid profiles in healthy untrained adults, whereas low-dose supplementation fails to produce significant improvements compared to training alone.

If you are new to resistance training, adding a moderate amount of cheese (providing ~13g of protein) on your workout days can help improve your body fat and cholesterol levels more than training alone. You do not need to consume large amounts of protein; a medium dose (approx. 216g of the specific cheese used) split around your workout is sufficient. Do not expect this to make you stronger faster than training alone, as strength gains were similar across all groups.

Vitamin D3 supplementation alone is the most cost-effective management strategy for sarcopenia in Iran, whereas combination therapies (Protein+Vitamin D, Protein+Vitamin D+Exercise) are not cost-effective despite higher clinical effectiveness.

For healthcare systems or individuals in Iran, Vitamin D3 supplementation is the most economically sensible intervention for managing sarcopenia. While adding protein and exercise improves health outcomes (QALYs), the high cost of these combinations makes them not cost-effective compared to Vitamin D alone. Focus on Vitamin D for the best economic return.

Resistance training responsiveness is highly heterogeneous, with non-responder rates ranging from 0% to 84% for muscle size, 0% to 44% for strength, and 37-42% for functional performance, indicating that individual ability to respond varies widely regardless of the intervention.

Do not assume resistance training will yield identical results for everyone. If you are not seeing expected gains in strength or size after 4-12 weeks, you may be a 'non-responder' for that specific protocol. This is common (up to 84% for muscle size in some studies). Consult a professional to adjust volume, intensity, or exercise selection rather than abandoning training entirely.

Carbohydrate reduction leads to a significant decrease in Alanine Aminotransferase (ALT) levels, indicating improved liver function, while HDL cholesterol may show a small decline.

Your liver function is likely to improve, as shown by a significant drop in ALT levels. However, be aware that HDL ('good') cholesterol may decrease slightly. This is a common finding with carbohydrate reduction and should be monitored by your doctor.

In older adults, daily coffee consumption is associated with a decrease in body fat percentage, whereas consuming coffee only a few times per week is associated with an increase in body fat percentage compared to daily consumers.

If you are an older adult, drinking coffee daily might be associated with lower body fat compared to drinking it sporadically. However, this effect is small, and the study suggests it may be indirect (e.g., via gut microbiota or appetite). Do not rely on coffee alone for fat loss; focus on overall diet and activity.

Frequent consumption of beer (a few times per week) and sweets (once a week or more) is associated with an increase in body fat percentage and a decrease in skeletal muscle mass in older adults.

For older adults, drinking beer a few times a week and eating sweets weekly or more is linked to higher body fat and lower muscle mass. Reducing the frequency of these items may help maintain body composition.

Tailoring type 2 diabetes lifestyle interventions (Medical Nutrition Therapy, in-person groups, or telephone groups) to patient preferences regarding learning style, schedule, and accountability improves engagement and adherence.

Do not force a single delivery format on all diabetic patients. Assess their preference for learning (social vs. individual), schedule flexibility, and need for accountability. Offer Medical Nutrition Therapy (MNT) for those needing flexibility and one-on-one accountability, telephone groups for those wanting peer support without travel, and in-person groups for those who value face-to-face interaction and structure. Matching the format to the patient's lifestyle increases the likelihood of sustained participation.

Eliminating in vivo digestibility requirements (PDCAAS) for protein content claims and relying solely on protein amount per serving aligns food labeling with dietary guidelines, promotes plant-based food consumption, and improves public health outcomes.

If you are eating enough total protein from varied sources, you do not need to worry about complex protein quality scores on labels. Focus on choosing plant-based protein sources (beans, lentils, soy) which are often disadvantaged by current labeling rules. This change helps you make healthier choices that lower saturated fat and increase fiber, supporting long-term health without needing to track complex metrics.

Higher overall hunger levels are associated with healthier meal timing habits, specifically achieving longer overnight fasts (≥ 13 hours) and eating less frequently late at night, contradicting the assumption that hunger prevents adherence to healthy meal timing.

If you are struggling to stick to a meal timing plan (like skipping breakfast or eating early dinner), don't assume hunger is your enemy. This research suggests that people who feel hungrier are actually more likely to achieve longer overnight fasts. Instead of eating to suppress hunger, view hunger as a sign that your body is adapting to the fasting window. Focus on consistency rather than comfort, as hunger may not be the barrier to adherence you think it is.

Higher body mass index (BMI) is associated with lower self-reported physical functioning and overall health-related quality of life (HRQoL) in people with overweight or obesity.

If you have overweight or obesity, your daily physical ability and general health perception are likely lower than average, and this tends to get worse as your BMI increases. This is a measurable health burden, not just a cosmetic issue, and addressing weight may improve your physical functioning.